Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Heartbeam, Inc. - Common Stock (NQ:BEAT)

1.750 -0.060 (-3.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,235
Open 1.860
Bid (Size) 1.660 (5)
Ask (Size) 2.000 (60)
Prev. Close 1.810
Today's Range 1.723 - 1.860
52wk Range 1.450 - 3.480
Shares Outstanding 34,260,799
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Strategic Collaboration with AccurKardia for Ambulatory ECG Recording and Analysis to Advance Cardiac Monitoring Care: HeartBeam, Inc. (Nasdaq: BEAT)
Via Get News
Topics Intellectual Property
Exposures Intellectual Property Product Safety
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Positive VALID-ECG Study Results Supporting 12-Lead ECG Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety

Performance

YTD
-25.5%
-25.5%
1 Month
-12.9%
-12.9%
3 Month
-19.4%
-19.4%
6 Month
-35.2%
-35.2%
1 Year
-12.9%
-12.9%

More News

Read More
HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology
From HeartBeam, Inc.
Via Business Wire
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) and AccurKardia Partner to Advance Remote ECG Monitoring
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring Innovation
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Reports Q4 and Full-Year 2024 Financial Results, Highlights FDA Clearance and Commercial Progress
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
HeartBeam Reports Fourth Quarter and Full Year 2024 Results
From HeartBeam, Inc.
Via Business Wire
Earnings Scheduled For March 13, 2025
Via Benzinga
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Present at Upcoming Investor and Industry Conferences
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 16-21, 2025
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Report Q4 and Full-Year 2024 Results on March 13
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Underwriter Exercises Option, Increasing Gross Proceeds to $11.5M
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam Announces Exercise and Closing of Underwriter’s Over-Allotment Option for Public Offering of Common Stock
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Prices $10 Million Public Offering at $1.70 Per Share
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam Announces Pricing of $10.0 Million Underwritten Public Offering of Common Stock
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Submits FDA Application for 12-Lead ECG Synthesis Software
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Present at JP Morgan 2025 Annual Healthcare Conference
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference
From HeartBeam, Inc.
Via Business Wire
HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures FDA Clearance for Innovative Arrhythmia Assessment Device
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Presents Positive Data for Groundbreaking Technology at AHA Conference
Via Investor Brand Network
HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Advances Toward Commercialization of Cardiac Care Technology with FDA Submissions and Key Leadership Appointments
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety

Frequently Asked Questions

Is Heartbeam, Inc. - Common Stock publicly traded?
Yes, Heartbeam, Inc. - Common Stock is publicly traded.
What exchange does Heartbeam, Inc. - Common Stock trade on?
Heartbeam, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Heartbeam, Inc. - Common Stock?
The ticker symbol for Heartbeam, Inc. - Common Stock is BEAT on the Nasdaq Stock Market
What is the current price of Heartbeam, Inc. - Common Stock?
The current price of Heartbeam, Inc. - Common Stock is 1.750
When was Heartbeam, Inc. - Common Stock last traded?
The last trade of Heartbeam, Inc. - Common Stock was at 04/30/25 04:00 PM ET
What is the market capitalization of Heartbeam, Inc. - Common Stock?
The market capitalization of Heartbeam, Inc. - Common Stock is 59.96M
How many shares of Heartbeam, Inc. - Common Stock are outstanding?
Heartbeam, Inc. - Common Stock has 60M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.